Publication
A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Prostate Neoplasmcivic_curation1.00
- drugCabazitaxelcivic_curation1.00
- drugDocetaxelcivic_curation1.00
- drugLinsitinibcivic_curation1.00
- geneIGF2civic_curation1.00
- variantIGF2 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25670080
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| IGF2 Overexpression3 | ||||||||
| Cabazitaxel + LinsitinibCombination | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12428OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC | civic |
| Cabazitaxel + Docetaxel + LinsitinibSubstitutes | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID414OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC | civic |
| Linsitinib | Malignant Prostate Neoplasm | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID412Increased IGF2 expression was shown to mediate chemotherapy resistance in several prostate cancer cell lines. The IGF1R/INSR inhibitor OSI-906 did not have a significant effect on chemotherapy resista… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC | civic |